In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
ICON predicts biotech trial demand will grow despite economic pressures
This article from Clinical Insider outlines ICON’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent ICON biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
From Vaccines to Oncology and Beyond: Tracking mRNA’s Progress
In this article, ICON’s Andreas Dreps and Martin Lachs discuss how the success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
-
Practical considerations for managing cell and gene therapy supply chains
In this article in Clinical Research News, Alyssa Gilliam, Vice President, CSM & IRT and Chad Crafford, Clinical Supplies Manager outline practical considerations for managing your CGT supply chain to minimise risk, mitigate cost and complexity.
-
48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
IMI Mobilise-D: The next generation of mobility research
In this article from International Pharmaceutical Industry, Gerard Quinn, VP, IT Innovation and Informatics, provides an overview on the Innovative Medicines Initiative (IMI) funded Mobilise-D project, which aims to develop a comprehensive system to analyse people’s gait using digital technologies, including sponsors worn on the body.
-
The power of tokenising clinical research
In this Intelligent Health.tech interview Kathleen Mandziuk, VP eClinical Development & Delivery, outlines ICON's clinical trial tokenisation solution and how it's poised to reshape evidence generation and research insights into drug safety and efficiency over time through advanced analytics.
-
Early protocol assessment for increased patient centricity
In this article in Applied Clinical Trials, Emily Mitchell, Executive Director, eClinical Development and Delivery, outlines how thorough assessment of protocols, whether for DCTs or hybrid clinical trials that incorporate decentralised components, can ensure that studies are designed to minimise patient burden while optimising opportunities to leverage data on a wider scale.
-
Devices regulation offers opportunities and challenges for medtech
In this piece from the Irish Times, Cynthia Nolte, Director, Regulatory Affairs, Strategic Regulatory Services outlines that while there are challenges with the EU Medical Devices Regulation, the requirements do provide manufacturers with an opportunity to audit portfolios and eliminate unprofitable products.
-
AI has the power to revolutionise drug discovery and design
In this article from the Irish Times, Gerard Quinn, VP of IT Innovation and Informatics provides insight on how artificial intelligence can support the drug development process in order to deliver new treatments to more people, faster.
-
Continued investment key to our success as a life sciences hotspot
In this Irish Times article, Brendan Brennan, CFO, outlines how Ireland’s strong culture of partnership and collaboration, in addition to scientific and technical expertise, has played an important part in the success of the life sciences industry in Ireland.
